Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04872543 · ClinicalTrials.gov registry record · Phase 2
A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
A Phase 2 study of Malignant Peripheral Nerve Sheath Tumors (MPNST), sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 7
- Study locations
NCT04872543: Recruiting Phase 2 study of Malignant Peripheral Nerve Sheath Tumors (MPNST), sponsored by Memorial Sloan Kettering Cancer Center.
NCT04872543 is a Phase 2 study of Malignant Peripheral Nerve Sheath Tumors (MPNST) that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 25 participants. The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04872543, a Phase 2 study of Malignant Peripheral Nerve Sheath Tumors (MPNST), is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to see whether the study drug ASTX727 is an effective treatment for people who have MPNST with a PCR2 mutation. ASTX727 is a combination of two drugs (cedazuridine and decitabine) that have been designed to target cancer cells with a PCR2 mutation and to disrupt the cells' ability to survive and grow. The study researchers think that the study drug allows decitabine to work better than decitabine given alone.
Conditions Studied
Interventions
- DRUG ASTX727
Study Locations (7)
New York
- Memorial Sloan Kettering Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-04-29 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04872543
The ClinicalTrials.gov registry entry for NCT04872543 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Peripheral Nerve Sheath Tumors (MPNST) appearing as the primary indexed condition, and to 1 intervention - of which ASTX727 is the first listed.
NCT04872543 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04872543 about?
NCT04872543 is a clinical study titled "A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)". The purpose of this study is to see whether the study drug ASTX727 is an effective treatment for people who have MPNST with a PCR2 mutation. ASTX727 is a combination of two drugs (cedazuridine and decitabine) that have been designed to target cancer cells with a PCR2 mutation and to disrupt the cel...
What is the current status of trial NCT04872543?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2021-04-29. Estimated completion is 2027-04.
What conditions does trial NCT04872543 study?
This clinical trial studies the following conditions: Malignant Peripheral Nerve Sheath Tumors (MPNST).
What interventions are being tested in trial NCT04872543?
The interventions under investigation include: ASTX727 (DRUG).
Who is sponsoring clinical trial NCT04872543?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04872543 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Peripheral Nerve Sheath Tumors (MPNST)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.